Table 4. False-positive report probability values for the associations between neuroblastoma susceptibility and the frequency of genotypes of the LMO1 gene.

Genotype	Crude OR (95% CI)	Pa	Statistical powerb	Prior probability
				0.25	0.1	0.01	0.001	0.0001
LMO1 rs110419 A > G
AG vs. AA	0.66 (0.47–0.91)	0.012	0.544	0.064	0.169	0.691	0.958	0.996
GG vs. AA	0.57 (0.36–0.90)	0.017	0.284	0.149	0.344	0.852	0.983	0.998
AG/GG vs. AA	0.64 (0.47–0.87)	0.004	0.368	0.033	0.093	0.531	0.919	0.991
AG/GG vs. AA
> 18	0.54 (0.36–0.81)	0.003	0.140	0.053	0.143	0.647	0.949	0.995
Males	0.63 (0.42–0.95)	0.027	0.382	0.173	0.386	0.873	0.986	0.999
Adrenal gland	0.36 (0.20–0.66)	0.001	0.027	0.098	0.247	0.783	0.973	0.997
Mediastinum	0.59 (0.37–0.92)	0.022	0.285	0.185	0.406	0.882	0.987	0.999
Stage III + IV	0.57 (0.38–0.85)	0.006	0.215	0.079	0.204	0.738	0.966	0.996
Protective genotypes
4 vs. 0–3	0.51 (0.32–0.81)	0.005	0.148	0.084	0.215	0.751	0.968	0.997
> 18	0.45 (0.24–0.87)	0.016	0.141	0.258	0.510	0.92	0.991	0.999
Males	0.41 (0.23–0.76)	0.004	0.076	0.139	0.326	0.842	0.982	0.998
Mediastinum	0.27 (0.11–0.68)	0.005	0.040	0.284	0.543	0.929	0.992	0.999
Stage I + II + 4s	0.43 (0.23–0.84)	0.013	0.115	0.248	0.497	0.916	0.991	0.999

^aChi-square test was used to calculate the genotype frequency distributions

^bStatistical power was calculated using the number of observations in the subgroup and the OR and P values in this table.